Velocity Clinical Research Partners with VCT to Combat Double Enrollment in Clinical Trials
核心洞察
Velocity Clinical Research (搜索) has implemented Verified Clinical Trials (搜索)' participant verification technology across its 80+ sites to prevent simultaneous enrollment in multiple clinical trials.
The integration leverages Advarra (搜索)'s Clinical Conductor management system through API connectivity, streamlining pre-screening processes and enhancing data accuracy across four countries.
This strategic partnership aims to protect patient safety, maintain data integrity, and reduce drug development costs by preventing duplicate enrollments in clinical trials.
Velocity Clinical Research (搜索) has taken a significant step forward in clinical trial safety and data integrity by partnering with Verified Clinical Trials (搜索) (VCT) to address the persistent challenge of double enrollment in clinical studies.
The collaboration introduces VCT's advanced participant verification technology across Velocity's network of more than 80 clinical trial sites. This systematic approach prevents subjects from simultaneously enrolling in multiple studies, addressing a critical issue in clinical research that can compromise both patient safety and research validity.
Technology Integration and Implementation
The partnership leverages Advarra (搜索)'s Clinical Conductor clinical trial management system, utilizing its application programming interface (API) to streamline enrollment status verification. This integration enhances pre-screening processes while reducing administrative burden and improving accuracy in participant tracking.
Impact on Patient Safety and Research Quality
Double enrollment in clinical trials poses significant risks to both participant health and research outcomes. "Some participants may inadvertently enroll in multiple trials, putting themselves and the research at risk," explains Nick Spittal, Chief Operations Officer at Velocity Clinical Research (搜索). The new system provides a technological safeguard against such occurrences.
Dr. Mitchell Efros, CEO and co-founder of VCT, emphasizes the significance of this implementation: "Velocity's decision to implement this system across all their sites, across four countries and two continents, underscores their leadership in patient safety and data integrity. This initiative is a powerful response to the growing issue of duplicate enrollment and professional participants."
Benefits for Stakeholders
The implementation offers multiple advantages for various stakeholders in the clinical research ecosystem:
- For Participants: Enhanced safety protocols and clearer enrollment guidance
- For Sponsors: Improved data quality and reliability
- For CROs: Additional confidence in research integrity
- For Research Sites: Streamlined verification processes and reduced administrative workload
Strategic Expansion and Future Implications
This technology rollout comes as Velocity continues its strategic growth, including recent expansion into Poland, which added access to a quarter of a million potential study participants. The partnership with VCT represents another step in Velocity's commitment to scaling clinical research operations while maintaining the highest standards of patient safety and data integrity.
"This partnership ensures that our sponsors receive the highest quality data while safeguarding participant safety, and is just another example of how scaling for a purpose introduces new benefits to the clinical research industry at large," concludes Spittal.